AU2009224623C1 - Novel method for the production of sulphonylpyrroles as HDAC inhibitors - Google Patents

Novel method for the production of sulphonylpyrroles as HDAC inhibitors Download PDF

Info

Publication number
AU2009224623C1
AU2009224623C1 AU2009224623A AU2009224623A AU2009224623C1 AU 2009224623 C1 AU2009224623 C1 AU 2009224623C1 AU 2009224623 A AU2009224623 A AU 2009224623A AU 2009224623 A AU2009224623 A AU 2009224623A AU 2009224623 C1 AU2009224623 C1 AU 2009224623C1
Authority
AU
Australia
Prior art keywords
formula
compound
alkyl
alkoxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009224623A
Other languages
English (en)
Other versions
AU2009224623B2 (en
AU2009224623A1 (en
Inventor
Thomas Maier
Bernd Muller
Matthias Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4SC AG
Original Assignee
4SC AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4SC AG filed Critical 4SC AG
Publication of AU2009224623A1 publication Critical patent/AU2009224623A1/en
Application granted granted Critical
Publication of AU2009224623B2 publication Critical patent/AU2009224623B2/en
Publication of AU2009224623C1 publication Critical patent/AU2009224623C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
AU2009224623A 2008-03-12 2009-03-11 Novel method for the production of sulphonylpyrroles as HDAC inhibitors Active AU2009224623C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08004567.7 2008-03-12
EP08004567A EP2100878A1 (en) 2008-03-12 2008-03-12 Novel method for the production of sulphonylpyrroles as HDAC inhibitors
PCT/EP2009/052870 WO2009112529A1 (en) 2008-03-12 2009-03-11 Novel method for the production of sulphonylpyrroles as hdac inhibitors

Publications (3)

Publication Number Publication Date
AU2009224623A1 AU2009224623A1 (en) 2009-09-17
AU2009224623B2 AU2009224623B2 (en) 2013-07-18
AU2009224623C1 true AU2009224623C1 (en) 2014-01-23

Family

ID=39639400

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009224623A Active AU2009224623C1 (en) 2008-03-12 2009-03-11 Novel method for the production of sulphonylpyrroles as HDAC inhibitors

Country Status (22)

Country Link
US (1) US8785659B2 (enExample)
EP (2) EP2100878A1 (enExample)
JP (1) JP5530939B2 (enExample)
KR (1) KR101571915B1 (enExample)
CN (1) CN101970404B (enExample)
AT (1) ATE519739T1 (enExample)
AU (1) AU2009224623C1 (enExample)
BR (1) BRPI0909752B8 (enExample)
CA (1) CA2719074C (enExample)
CY (1) CY1111994T1 (enExample)
DK (1) DK2265580T3 (enExample)
EA (1) EA017929B1 (enExample)
ES (1) ES2370592T3 (enExample)
IL (1) IL207995A (enExample)
MX (1) MX2010010015A (enExample)
NZ (1) NZ587824A (enExample)
PL (1) PL2265580T3 (enExample)
PT (1) PT2265580E (enExample)
SI (1) SI2265580T1 (enExample)
UA (1) UA102091C2 (enExample)
WO (1) WO2009112529A1 (enExample)
ZA (1) ZA201006422B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
WO2017178577A1 (en) 2016-04-14 2017-10-19 4Sc Ag Medical application of resminostat in asian patients
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087724A2 (en) * 2004-03-11 2005-09-22 Altana Pharma Ag Sulphonylpyrroles as hdac inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
DE69221290T2 (de) * 1991-12-10 1998-01-15 Shionogi & Co Auf aromatischen sulfonamiden basierende hydroxamsäurederivate
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
DE602006007558D1 (de) * 2005-03-15 2009-08-13 4Sc Ag N-sulfonylpyrrole und ihre verwendung als histondeacetylaseinhibitoren
EA018698B1 (ru) 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
KR101256846B1 (ko) 2005-09-21 2013-04-24 4에스체 악티엔게젤샤프트 Ｈｄａｃ의 억제제로서의 신규한 설포닐피롤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087724A2 (en) * 2004-03-11 2005-09-22 Altana Pharma Ag Sulphonylpyrroles as hdac inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCH "March's Advanced organic Chemistry", 5th Edition, 2001, Chapter 10. *
SITTIG "Pharmaceutical Manufacturing Encyclopedia", 2nd Edition, 1988, 1124-1125. *

Also Published As

Publication number Publication date
US20110105568A1 (en) 2011-05-05
EP2265580A1 (en) 2010-12-29
DK2265580T3 (da) 2011-10-31
KR101571915B1 (ko) 2015-11-25
ZA201006422B (en) 2011-10-26
BRPI0909752B8 (pt) 2021-05-25
EA201001270A1 (ru) 2011-04-29
PT2265580E (pt) 2011-11-21
AU2009224623B2 (en) 2013-07-18
IL207995A0 (en) 2010-12-30
NZ587824A (en) 2012-05-25
EA017929B1 (ru) 2013-04-30
US8785659B2 (en) 2014-07-22
ES2370592T3 (es) 2011-12-20
AU2009224623A1 (en) 2009-09-17
CA2719074C (en) 2017-01-17
HK1150319A1 (en) 2011-11-25
IL207995A (en) 2013-04-30
JP5530939B2 (ja) 2014-06-25
EP2265580B1 (en) 2011-08-10
CN101970404B (zh) 2013-05-08
WO2009112529A1 (en) 2009-09-17
EP2100878A1 (en) 2009-09-16
ATE519739T1 (de) 2011-08-15
BRPI0909752B1 (pt) 2020-11-24
JP2011513467A (ja) 2011-04-28
MX2010010015A (es) 2011-04-05
CY1111994T1 (el) 2015-11-04
BRPI0909752A2 (pt) 2015-10-06
SI2265580T1 (sl) 2011-12-30
PL2265580T3 (pl) 2012-01-31
KR20100121656A (ko) 2010-11-18
CN101970404A (zh) 2011-02-09
CA2719074A1 (en) 2009-09-17
UA102091C2 (ru) 2013-06-10

Similar Documents

Publication Publication Date Title
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
CN108530310B (zh) 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
CN113754653A (zh) 一种kras g12c抑制剂化合物及其用途
ES2993711T3 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2023061368A1 (zh) 一类羟肟酸衍生物及其应用
AU2009224623B2 (en) Novel method for the production of sulphonylpyrroles as HDAC inhibitors
CN102180826B (zh) 含α氨基酸结构的组蛋白去乙酰化酶抑制剂及其用途
WO2013170757A1 (zh) 4-氨基喹唑啉异羟肟酸类化合物及作为抗肿瘤药物应用
JP2021510152A (ja) Ｌｓｄ１とｈｄａｃとを標的として同時に阻害する化合物及びその用途
CN108689937A (zh) 吲唑类化合物及其在制备ido抑制剂类药物上的用途
WO2016107227A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
EP4629984A1 (en) Development of potent dual hdac/brd4 inhibitors
HK1150319B (en) Novel method for the production of sulphonylpyrroles as hdac inhibitors
WO2017011408A1 (en) Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same
WO2016107541A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
CN111548286B (zh) 一种具有hdac3抑制活性的psa衍生物及其应用
WO2026103775A1 (zh) 一种苯甲酰胺类衍生物及其用途
KR20180071889A (ko) 신규한 n-히드록시벤즈아미드 및 이의 용도
CN118459418A (zh) 一种异羟肟酸类hdac抑制剂及其在制备抗肿瘤药物中的应用
CN102249958B (zh) 苯甲酰氨类组蛋白去乙酰化酶抑制剂
BR112020000564A2 (pt) novos derivados de heteroarilamida como inibidores seletivos das histonas desacetilases 1 e/ou 2 (hdac1-2)
CA2957566A1 (en) Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 SEP 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 SEP 2013

FGA Letters patent sealed or granted (standard patent)